CCM
YARW

Corsair Capital Management’s Yarrow Bioscience YARW Stock Holding History

Corsair Capital Management’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,000
Closed -$16.8K – 191
2025
Q3 		$16.8K Buy
1,000
+800
+400% +$26.2K ﹤0.01% 166
2025
Q2 		$16.5K Buy
+200
New +$13K ﹤0.01% 151

Other funds holding YARW

SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
DI
Deeter Investments Austin, Texas $468M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
TC
T3 Companies New York $93.7M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $136M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Corsair Capital Management's YARW Position: Q4 2025 in Review

Corsair Capital Management sold out of Yarrow Bioscience (YARW) in Q4 2025, closing a stake of 1,000 shares — an estimated $16.8K sold.

Corsair Capital Management first reported a position in YARW in Q2 2025 and held it in 2 quarters. The position peaked at $16.8K in Q3 2025. 42 funds tracked by Wall St. Rank hold YARW as of Q4 2025.

  • Corsair Capital Management reported no remaining Yarrow Bioscience position as of Q4 2025 after selling out during the quarter.
  • Corsair Capital Management sold 1,000 Yarrow Bioscience shares in Q4 2025, an estimated $16.8K.
  • Corsair Capital Management first reported a position in Yarrow Bioscience in Q2 2025 and held it in 2 quarters.
  • Corsair Capital Management's Yarrow Bioscience position peaked at $16.8K in Q3 2025.
  • 42 funds tracked by Wall St. Rank held Yarrow Bioscience as of Q4 2025.

Based on Corsair Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.